Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Acquired by Plancorp LLC

Plancorp LLC lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 155.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,610 shares of the company’s stock after purchasing an additional 43,000 shares during the quarter. Plancorp LLC’s holdings in Recursion Pharmaceuticals were worth $530,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. purchased a new stake in Recursion Pharmaceuticals in the first quarter valued at about $26,000. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after acquiring an additional 6,036 shares in the last quarter. Midwest Financial Group LLC purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at approximately $90,000. Gilman Hill Asset Management LLC acquired a new stake in Recursion Pharmaceuticals in the 2nd quarter worth approximately $101,000. Finally, International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals during the 2nd quarter worth approximately $101,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Up 1.7 %

Shares of Recursion Pharmaceuticals stock opened at $6.76 on Wednesday. The stock has a market cap of $1.90 billion, a PE ratio of -4.22 and a beta of 0.82. The firm has a fifty day moving average price of $7.20 and a 200 day moving average price of $8.43. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. During the same quarter in the previous year, the business posted ($0.38) EPS. The business’s quarterly revenue was up 30.9% on a year-over-year basis. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. KeyCorp reduced their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Leerink Partners cut their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average price target of $9.40.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total transaction of $108,860.97. Following the sale, the director now owns 7,177,116 shares of the company’s stock, valued at approximately $68,254,373.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the transaction, the director now owns 7,177,116 shares in the company, valued at $68,254,373.16. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total value of $92,550.00. Following the sale, the chief financial officer now owns 1,377,756 shares in the company, valued at $8,500,754.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 231,682 shares of company stock valued at $1,663,867. 15.75% of the stock is owned by company insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.